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Disturbances of skin barrier function occur in several skin diseases, e.g., atopic dermatitis (AD),
irritant/allergic contact dermatitis (ICD, ACD). Skin barrier damage triggers the production of
cytokines that stimulate lipogenesis which may also cause inflammatory processes. The aim of this
study was to evaluate the efficacy of a topical skin lipid mixture in the treatment of ICD, ACD
and AD. 580 consecutive patients suffering from ICD, ACD or AD were treated with a skin lipid
mixture containing ceramide-3 and patented nanoparticles. Patients received the lipid mixture
alone or in combination with topical corticosteroids until clearance or for 8 weeks. Both treatment
groups statistically improved all parameters considered at week 4 and 8 as compared to baseline.
Between the 2 treatment groups, there was a statistically significant difference in favour of com-
bined therapy for (ICD, ACD, AD, respectively): erythema, pruritus and overall disease severity;
erythema and pruritus; erythema, pruritus, fissuring and overall disease severity. No statistically
significant difference was found for (ICD, ACD, AD, respectively): dryness, scaling and fissuring;
scaling, fissuring and overall disease severity; dryness and scaling. Between the 2 ACD treatment
groups, there was a statistically significant difference in favour of the skin lipid mixture for dryness.
In conclusion, the study shows that balanced lipid mixtures are effective in improving barrier
properties and the clinical condition of the skin in contact dermatitis.
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ic dermatitis; irritant contact dermatitis. C Munksgaard, 2001.
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The cutaneous permeability barrier, localized in
the stratum corneum (SC) interstices, is consti-
tuted by lamellar bilayers, rich in cholesterol, free
fatty acids and ceramides (1–4). Topical treatment
with either an organic solvent, acetone, detergents
or other irritants, disrupts this barrier by removal
of these lipids (2–5). In response to barrier disrup-
tion, a homeostatic repair response is initiated
within the nucleated epidermis, which results in the
rapid restoration of lipids in the SC and normal-
ization of barrier function; this homeostatic re-
sponse includes an increase in epidermal synthesis
of all 3 of the above-mentioned skin lipid classes
(6–8). The requirement for an increase in lipid syn-
thesis for barrier repair is shown by the obser-
vation that inhibition of either cholesterol, fatty
acid or sphingolipid synthesis alone, leads to a de-
lay in barrier repair (9–11). Thus, lipid production
in the nucleated layers of the epidermis provides
the lipids required for barrier restoration.
Recent studies have shown that application of
any 1 or 2 of these lipid classes to damaged skin
impedes rather than facilitates the rate of barrier
repair, as can be detected by transepidermal water
loss (TEWL) (11). In contrast, when members of
all 3 key lipid classes are supplied together, normal
rates of barrier repair occur. Furthermore, follow-
ing acute barrier disruption, exogenous physiol-
ogic lipids, whether in complete or incomplete
mixtures, quickly permeate the SC, are taken up
by the nucleated layers of the epidermis, and are
incorporated into lamellar bodies (LB).
Then, depending on the lipid composition and
proportion, normal or abnormal LB are formed,
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Table 1. Sex and age profiles of the patients participating to the
study
Skin lipid Combined
Variable mixture therapy
sex (M/F), ACD group 11/24 61/104
age, ACD group 36.8∫9.18 35.7∫12.7
sex (M/F), ICD group 34/89 64/90
age, ICD group 38.2∫13.9 38.5∫14.7
sex (M/F), AD group 13/11 33/32
age, AD group 31.4∫11.1 27.3∫11.6
Table 2. Number patients/disease and corresponding assigned
treatment
Treatment groups ACD ICD AD
missing 5 6 2
skin lipid mixture 35 123 24
combined therapy 166 154 65
total patients/disease 206 283 91
total patients 580
leading to the formation of either normal or ab-
normal lamellar unit structures in the SC inters-
tices (11, 12).
The present study was designed to evaluate the
efficacy of a skin lipid mixture in the treatment of
conditions involving barrier damage, such as atop-
ic dermatitis (AD), and irritant/allergic contact
dermatitis (ICD, ACD).
Materials and Methods
580 consecutive patients (206 with ACD, 283 with
ICD and 91 with AD) entered the study (Table 1).
Fig. 1. *Ωp,0.05 in favour of group B versus group A. AΩpatients treated with skin lipid mixture alone; BΩpatients treated with
skin lipid mixturepitopical corticosteroids.
Patients were divided into 2 treatment groups: skin
lipid mixture alone and skin lipid mixture plus top-
ical corticosteroids. 13 patients (5 with ACD, 6
with ICD and 2 with AD) were excluded from stat-
istical analysis due to missing assigned treatment
group.
All patients were treated with a skin lipid mix-
ture containing ceramide-3, cholesterol, palmitic
acid and oleic acid in a water-in-oil vehicle con-
taining a patented nanoparticles technology (Re-
positolA/AlfasonA Repair/Locobase RepairA/Nou-
rivaTM Repair; Yamanouchi). The product was
topically applied 1–2¿ a day, alone (group A) or
in combination with topical corticosteroids (e.g.,
hydrocortisone-17-butyrate, betamethasone-valer-
ate, prednicarbate, desoxymethasone, mometa-
sone-furoate, prednisolone-aceponate, budesonide)
(group B). The different topical corticosteroid
preparations were selected in the centers partici-
pating to the study on the basis of the clinical se-
verity of symptoms. The skin lipid mixture was ap-
plied until healing occurred or for a maximum
period of 8 weeks. Dermatologists randomly as-
signed the patient to single or combined therapy.
The severity of skin lesions was evaluated at base-
line and after 4 and 8 weeks. The following symp-
toms were evaluated: dryness, scaling, erythema,
pruritus, fissuring and overall disease severity,
using a visual 4-score rating scale (0Ωnone, 1Ω
mild, 2Ωmoderate, 3Ωsevere).
Statistical analysis
All data were summarized using a descriptive stat-
istical technique. The results were expressed as a
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Fig. 2. *Ωp,0.05 in favour of group A versus group B; piΩp,0.05 in favour of group B versus group A. AΩpatients treated with
skin lipid mixture alone; BΩpatients treated with skin lipid mixturepitopical corticosteroids.
mean∫SD. The 2-way ANOVA test was used for
statistical evaluation at scheduled visits versus
baseline in each group; for multiple comparison
t-Dunnet test was used. Between the 2 treatment
groups, the comparison of the median values on
the differences observed at each scheduled visit
versus baseline was performed using t-test for inde-
pendent data. Non-parametric statistics were also
used where appropriate. Statistical significance was
defined as p,0.05.
Results
Irritant contact dermatitis
Both treatment groups (Table 2) had a statistically
significant improvement in all parameters con-
sidered at week 4 and at week 8 versus baseline
(Fig. 1, Fig. 4).
The mean values of the differences after 4 and 8
weeks versus baseline showed no statistically-sig-
nificant difference between the 2 treatment groups
for dryness (pΩ0.281 and pΩ0.300, respectively;
ns), scaling (pΩ0.589 and pΩ0.261, respectively;
ns) and fissuring (pΩ0.097 and pΩ0.390, respec-
tively; ns), (Fig. 1).
A statistically-significant difference in favour of
combined therapy was shown for erythema
(p,0.001 and p,0.001, respectively), pruritus
(p,0.001 and p,0.001, respectively) and overall
severity disease (pΩ0.008 and pΩ0.031, respec-
tively), (Fig. 1, Fig. 4).
Allergic contact dermatitis
Both treatment groups had a statistically signifi-
cant improvement in all parameters considered at
week 4 and at week 8 versus baseline (Fig. 2,
Fig. 4). The mean values of the differences after
4 and 8 weeks versus baseline showed no statisti-
cally-significant difference between the 2 treat-
ment groups for scaling (pΩ0.086 and pΩ0.355,
respectively; ns), fissuring (pΩ0.847 and pΩ0.726,
respectively; ns) and overall disease severity (pΩ
0.528 and pΩ0.600, respectively; ns), (Fig. 2, Fig.
4).
A statistically-significant difference in favour of
the skin lipid mixture was shown in dryness at
week 4 (p,0.001; pΩns at week 8); in favour of
combined therapy for erythema at week 8 only (pΩ
0.034; pΩns at week 4) and for pruritus at week 4
and at week 8 (respectively pΩ0.019 and pΩ0.041)
(Fig. 2).
Atopic dermatitis
Both treatment groups had a statistically-signifi-
cant improvement in all parameters considered at
week 4 and at week 8 versus baseline (Fig. 3, Fig.
4). The mean values of the differences after 4 and
8 weeks versus baseline showed no statistically-sig-
nificant difference between the 2 treatment groups
for dryness (pΩ0.612 and pΩ0.613, respectively;
ns) and scaling (pΩ0.125 and pΩ0.166, respec-
tively; ns) (Fig. 3).
A statistically-significant difference in favour of
combined therapy was shown for erythema at week
4 (pΩ0.041; pΩns at week 8), pruritus at week 8
(pΩ0.018; pΩns at week 4), fissuring at week 4 and
week 8 (pΩ0.002 and pΩ0.031), and overall sever-
ity disease at week 4 (pΩ0.007; pΩns at week 8)
(Fig. 3, Fig. 4).
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Fig. 3. *Ωp,0.05 in favour of group B versus group A. AΩpatients treated with skin lipid mixture alone; BΩpatients treated with
skin lipid mixturepitopical corticosteroids.
Fig. 4. *Ωp,0.05 in favour of group B versus group A. AΩpatients treated with skin lipid mixture alone; BΩpatients treated with
skin lipid mixturepitopical corticosteroids.
Discussion
Disturbance of skin barrier function occurs in a
number of skin diseases, including atopic derma-
titis (AD) and irritant/allergic contact dermatitis
(ICD, ACD).
The skin barrier can be damaged in several
ways, such as by frequent exposure to mechanical
stress (construction workers, carpenters), lipid ex-
traction by oils, grease or organic solvents, long-
term exposure to water (cleaners, kitchen workers,
fish or paper industry workers), detergents or
liquid soap (housewives). As a consequence of
TEWL increase, the skin becomes dry. Skin barrier
disturbance triggers the production of cytokines
which stimulate lipogenesis but can also increase
inflammatory responses and induce the appear-
ance of eczema. As a result of a damaged skin bar-
rier, irritant and sensitizing substances can more
easily penetrate the skin, increasing the risk of de-
velopment of ICD/ACD. Topically, application of
a lipid mixture has been shown to be useful in pro-
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viding ‘‘ready to use’’ lipids to the SC in order to
promote repair of a deranged barrier; however, the
usefulness of this model has been mainly shown in
animal models and few data in humans are avail-
able (13–16). Furthermore, these studies have been
performed using standardized irritation models,
but not in real clinical conditions, where many en-
vironmental and in-use cofactors can influence the
outcome of therapy.
Our study shows how an optimized lipid mixture
included in nanoparticles (17) can be helpful in
promoting barrier repair and improving skin con-
dition in different dermatoses characterized by
barrier damage.
Both treatment groups improved significantly at
weeks 4 and 8 both in AD and ICD/ACD. In par-
ticular, no significant differences between the treat-
ments at weeks 4 and 8 were detected for dryness,
scaling, fissuring (ICD/ACD only) and overall dis-
ease severity (ACD only) (i.e., the clinical par-
ameters more related to SC efficiency) in all the
pathologies investigated. The combined treatment
(lipidspitopical corticosteroids) leads to a more
significant effect on erythema, presumably due to
the corticosteroid’s vasoactive characteristics, and
on pruritus as a probable consequence of a sup-
pressed release of inflammatory mediators. The
overall disease severity was in favour of the com-
bined treatment in ICD and AD. These findings
support the view that optimized lipid mixtures can
be helpful in improving barrier properties in clin-
ical conditions, even though not exerting a phar-
macological effect. Therefore, their use could be
indicated as a support for barrier restructuring
during the acute phases of ICD/ACD or AD in
association with pharmacological therapy, or as a
preventive maintenance measure to counteract bar-
rier disruption and reduce risk factors before the
onset of clinical signs of irritant contact derma-
titis.
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